Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+/-)Nicotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 0.97 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.97 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.97 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.97 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.97 |
| ▸ | HTR3B | O95264 | 1/20 | 0.97 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.97 |
| ▸ | CHRNG | P07510 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.97 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+/-)Nicotine SCHEMBL30339296 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL676683 | 0.98 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL4729900 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL11976729 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL10909351 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL308101 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL1724652 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL2599622 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL797620 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL10909353 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 871 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232006-B1 | A NEW POWDER COMPOSITION | LIW INNOVATION AB (SE) | 2026-04-15 | — | — | EP | claimed |
| US-20260014135-A1 | NICOTINE TABLET | FERTIN PHARMA A/S (DK) | 2026-01-15 | — | — | US | claimed |
| US-20250386851-A1 | ENCAPSULATED COMPOSITIONS FOR ORAL USE | MODORAL BRANDS INC (US) | 2025-12-25 | — | — | US | claimed |
| EP-4635485-A1 | NICOTINE MICROPELLET COMPOSITION, NICOTINE MICROPELLET ORAL POUCH, AND METHOD FOR PREPARING SAME | Maifeng (Zhuhai) Technology Co., Ltd. (CN) | 2025-10-22 | — | — | EP | claimed |
| US-12433881-B2 | Nicotine tablet | FERTIN PHARMA A/S (DK) | 2025-10-07 | — | — | US | claimed |
| US-12408692-B2 | Smokeless tobacco pastille | R.J. REYNOLDS TOBACCO COMPANY (US) | 2025-09-09 | — | — | US | claimed |
| EP-1803444-B2 | A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) | NICONOVUM AB (SE) | 2025-08-06 | — | — | EP | claimed |
| WO-2025118169-A1 | NICOTINE POUCH ABSORBED BY ORAL MUCOSA AND PREPARATION METHOD THEREFOR | 麦丰(珠海)科技有限公司 | 2025-06-12 | — | — | WO | claimed |
| US-20250152573-A1 | ORAL COMPOSITIONS WITH REDUCED WATER CONTENT | NICOVENTURES TRADING LTD (GB) | 2025-05-15 | — | — | US | claimed |
| EP-4447714-B1 | NICOTINE TABLET | FERTIN PHARMA AS (DK) | 2025-05-14 | — | — | EP | claimed |
| CN-1997350-A | Tobacco alkaloid releasing chewing gum | FERTIN PHARMA AS (DK) | 2007-07-11 | — | — | CN | claimed |
| EP-1803443-A2 | A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) | NicoNovum AB (SE) | 2007-07-04 | — | — | EP | claimed |
| EP-1803444-A2 | A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) | NicoNovum AB (SE) | 2007-07-04 | — | — | EP | claimed |
| EP-1578422-B1 | A PHYSICALLY AND CHEMICALLY STABLE NICOTINE AND MICORCRYSTALLINE CELLULOSE CONTAINING PARTICULATE MATERIAL | NICONOVUM AB (SE) | 2007-04-11 | — | — | EP | claimed |
| EP-1761243-A1 | TOBACCO ALKALOID RELEASING CHEWING GUM | Fertin Pharma A/S (DK) | 2007-03-14 | — | — | EP | claimed |
| CN-1738621-A | Physically and chemically stable nicotine-containing particulate material | NICONOVUM AB (SE) | 2006-02-22 | — | — | CN | claimed |
| WO-2006000232-A1 | TOBACCO ALKALOID RELEASING CHEWING GUM | FERTIN PHARMA A/S (DK) | 2006-01-05 | — | — | WO | claimed |
| EP-1578422-A2 | A PHYSICALLY AND CHEMICALLY STABLE NICOTINE-CONTAINING PARTICULATE MATERIAL | Niconovum AB (SE) | 2005-09-28 | — | — | EP | claimed |
| US-20040191322-A1 | Rapid release and absorption through oral mucosa; using microcrystalline cellulose | MODORAL BRANDS INC. | 2004-09-30 | — | — | US | claimed |
| WO-2004056363-A2 | A PHYSICALLY AND CHEMICALLY STABLE NICOTINE-CONTAINING PARTICULATE MATERIAL | NICONOVUM AB (SE) | 2004-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250386851-A1 | ENCAPSULATED COMPOSITIONS FOR ORAL USE | SORD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1 | CHRNB2 666/4885CHRNA4 219/4885ALDH1A1 3453/4885 |
| US-20260014135-A1 | NICOTINE TABLET | TAS2R39, TAS2R40, TAS2R42 | CHRNB2 683/4885CHRNA4 262/4885ALDH1A1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.